Share-based Payment Arrangement, Expense of NRX Pharmaceuticals, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
NRX Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • NRX Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $68,000, a 30% decline year-over-year.
  • NRX Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $197,000.
  • NRX Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $486,000, a 26% increase from 2023.
  • NRX Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $387,000, a 83% decline from 2022.
  • NRX Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,321,000, a 70% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

NRX Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $197,000 $68,000 -$29,000 -30% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2024 Q3
Q2 2025 $226,000 $67,000 -$30,000 -31% 01 Apr 2025 30 Jun 2025 10-Q 18 Aug 2025 2024 Q2
Q1 2025 $256,000 $12,000 -$230,000 -95% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2024 Q1
Q4 2024 $486,000 $50,000 +$1,253,000 01 Oct 2024 31 Dec 2024 10-K 14 Mar 2025 2024 FY
Q3 2024 $767,000 $97,000 -$254,000 -72% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2024 Q3
Q2 2024 $513,000 $97,000 -$447,000 -82% 01 Apr 2024 30 Jun 2024 10-Q 18 Aug 2025 2024 Q2
Q1 2024 $66,000 $242,000 -$453,000 -65% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2024 Q1
Q4 2023 $387,000 $1,203,000 -$662,000 -122% 01 Oct 2023 31 Dec 2023 10-K 14 Mar 2025 2024 FY
Q3 2023 $1,049,000 $351,000 -$190,000 -35% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $1,239,000 $544,000 -$443,000 -45% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $1,682,000 $695,000 -$639,000 -48% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $2,321,000 $541,000 -$2,111,000 -134% 01 Oct 2022 31 Dec 2022 10-Q 14 Aug 2023 2023 Q2
Q3 2022 $4,432,000 $541,000 -$1,019,000 -65% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $5,451,000 $987,000 -$3,296,000 -77% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $8,747,000 $1,334,000 +$962,000 +259% 01 Jan 2022 31 Mar 2022 10-Q 16 May 2022 2022 Q1
Q4 2021 $7,785,000 $1,570,000 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 $1,560,000 +$1,369,250 +718% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $4,283,000 +$4,189,534 +4482% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $372,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 $190,750 01 Jul 2020 30 Sep 2020 10-Q/A 12 Aug 2022 2021 Q3
Q2 2020 $93,466 01 Apr 2020 30 Jun 2020 10-Q/A 12 Aug 2022 2021 Q2

NRX Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $486,000 +$99,000 +26% 01 Jan 2024 31 Dec 2024 10-K 14 Mar 2025 2024 FY
2023 $387,000 -$1,934,000 -83% 01 Jan 2023 31 Dec 2023 10-K 14 Mar 2025 2024 FY
2022 $2,321,000 -$5,464,000 -70% 01 Jan 2022 31 Dec 2022 10-Q 14 Aug 2023 2023 Q2
2021 $7,785,000 +$7,055,000 +966% 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2020 $730,000 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.